Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3820768 in Advanced Germ Cell Tumours, Endometrial Cancer, or Ovarian Cancer
NCT07306559Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2026
- Primary completion
- Sep 2029
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 6
01
Overview
Phase 1, open-label trial of BI 3820768 in germ cell tumor (GCT), endometrial cancer (EC) and ovarian cancer (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of treatment-emergent adverse events at 3 years and Occurrence of Dose-Limiting Toxicities at 3 years. Started Feb 2026; status: recruiting.
02
Drugs
BI 3820768
03
Conditions
germ cell tumor (GCT)endometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on NCT07306559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306559.